In This Article:
The Australian market has shown resilience, with the ASX200 bouncing back to pre-tariff levels despite looming US tariffs on key sectors such as copper and pharmaceuticals. In this climate of cautious optimism, investors might find opportunities in penny stocks—companies that are smaller or newer but can offer substantial growth potential at lower price points. While the term "penny stocks" may seem dated, these investments continue to hold promise when supported by strong financials and robust fundamentals.
Top 10 Penny Stocks In Australia
| Name | Share Price | Market Cap | Financial Health Rating |
| CTI Logistics (ASX:CLX) | A$1.685 | A$135.72M | ★★★★☆☆ |
| EZZ Life Science Holdings (ASX:EZZ) | A$1.53 | A$72.17M | ★★★★★★ |
| IVE Group (ASX:IGL) | A$2.47 | A$380.83M | ★★★★★☆ |
| GTN (ASX:GTN) | A$0.60 | A$115.38M | ★★★★★★ |
| Bisalloy Steel Group (ASX:BIS) | A$3.38 | A$160.38M | ★★★★★★ |
| Regal Partners (ASX:RPL) | A$1.88 | A$631.99M | ★★★★★★ |
| Navigator Global Investments (ASX:NGI) | A$1.70 | A$833.14M | ★★★★★☆ |
| SHAPE Australia (ASX:SHA) | A$3.00 | A$248.22M | ★★★★★★ |
| NRW Holdings (ASX:NWH) | A$2.60 | A$1.19B | ★★★★★☆ |
| LaserBond (ASX:LBL) | A$0.37 | A$43.53M | ★★★★★★ |
Click here to see the full list of 987 stocks from our ASX Penny Stocks screener.
Let's review some notable picks from our screened stocks.
Macmahon Holdings
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Macmahon Holdings Limited offers surface and underground mining, mining support, and civil infrastructure services to mining companies in Australia and Southeast Asia, with a market cap of A$580.66 million.
Operations: The company generates revenue from providing surface and underground mining, mining support, and civil infrastructure services across Australia and Southeast Asia.
Market Cap: A$580.66M
Macmahon Holdings Limited has recently secured a significant contract extension at the Byerwen coking coal mine, adding approximately A$900 million to its order book without requiring new capital expenditures. Despite this positive development, the company faces challenges such as declining net profit margins and negative earnings growth over the past year. The company's Return on Equity remains low at 7%, and its board of directors is relatively inexperienced with an average tenure of 1.2 years. However, Macmahon's debt level is satisfactory, with strong coverage by operating cash flow and interest payments well covered by EBIT.
-
Jump into the full analysis health report here for a deeper understanding of Macmahon Holdings.
-
Learn about Macmahon Holdings' future growth trajectory here.
Race Oncology
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Race Oncology Limited is a clinical stage biopharmaceutical company focused on developing treatments for cancer patients with unmet needs, and it has a market cap of A$176.33 million.